455 related articles for article (PubMed ID: 35840984)
1. Emerging strategies to overcome resistance to third-generation EGFR inhibitors.
Shi K; Wang G; Pei J; Zhang J; Wang J; Ouyang L; Wang Y; Li W
J Hematol Oncol; 2022 Jul; 15(1):94. PubMed ID: 35840984
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
[TBL] [Abstract][Full Text] [Related]
3. Emerging treatment for advanced lung cancer with EGFR mutation.
Inal C; Yilmaz E; Piperdi B; Perez-Soler R; Cheng H
Expert Opin Emerg Drugs; 2015; 20(4):597-612. PubMed ID: 26153235
[TBL] [Abstract][Full Text] [Related]
4. [Mechanisms of Resistance to the Third-generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer].
Ni L; Nie L
Zhongguo Fei Ai Za Zhi; 2018 Feb; 21(2):110-115. PubMed ID: 29526178
[TBL] [Abstract][Full Text] [Related]
5. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
Zhang K; Yuan Q
J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
[TBL] [Abstract][Full Text] [Related]
6. Recent updates on the resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors and resistance reversion strategies in lung cancer.
Tripathi SK; Pandey K; Rengasamy KRR; Biswal BK
Med Res Rev; 2020 Nov; 40(6):2132-2176. PubMed ID: 32596830
[TBL] [Abstract][Full Text] [Related]
7. The new opportunities in medicinal chemistry of fourth-generation EGFR inhibitors to overcome C797S mutation.
He J; Zhou Z; Sun X; Yang Z; Zheng P; Xu S; Zhu W
Eur J Med Chem; 2021 Jan; 210():112995. PubMed ID: 33243531
[TBL] [Abstract][Full Text] [Related]
8. Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment.
Shi P; Oh YT; Zhang G; Yao W; Yue P; Li Y; Kanteti R; Riehm J; Salgia R; Owonikoko TK; Ramalingam SS; Chen M; Sun SY
Cancer Lett; 2016 Oct; 380(2):494-504. PubMed ID: 27450722
[TBL] [Abstract][Full Text] [Related]
9. Three generations of epidermal growth factor receptor tyrosine kinase inhibitors developed to revolutionize the therapy of lung cancer.
Zhang H
Drug Des Devel Ther; 2016; 10():3867-3872. PubMed ID: 27920501
[TBL] [Abstract][Full Text] [Related]
10. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.
Tan CS; Cho BC; Soo RA
Lung Cancer; 2016 Mar; 93():59-68. PubMed ID: 26898616
[TBL] [Abstract][Full Text] [Related]
11. Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: from mechanism analysis to clinical strategy.
Zhao Y; Wang H; He C
J Cancer Res Clin Oncol; 2021 Dec; 147(12):3653-3664. PubMed ID: 34661758
[TBL] [Abstract][Full Text] [Related]
12. Third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer.
Pirker R
Curr Opin Oncol; 2016 Mar; 28(2):115-21. PubMed ID: 26720671
[TBL] [Abstract][Full Text] [Related]
13. ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib.
Li Y; Zang H; Qian G; Owonikoko TK; Ramalingam SR; Sun SY
Cancer; 2020 Mar; 126(6):1339-1350. PubMed ID: 31821539
[TBL] [Abstract][Full Text] [Related]
14. EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research.
Dong RF; Zhu ML; Liu MM; Xu YT; Yuan LL; Bian J; Xia YZ; Kong LY
Pharmacol Res; 2021 May; 167():105583. PubMed ID: 33775864
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors.
Wang S; Song Y; Yan F; Liu D
Front Med; 2016 Dec; 10(4):383-388. PubMed ID: 27770386
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics.
Chung C
J Oncol Pharm Pract; 2016 Jun; 22(3):461-76. PubMed ID: 25855240
[TBL] [Abstract][Full Text] [Related]
17. Addressing epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer.
Noda S; Kanda S
Expert Rev Respir Med; 2016; 10(5):547-56. PubMed ID: 26959310
[TBL] [Abstract][Full Text] [Related]
18. Targeting Acquired and Intrinsic Resistance Mechanisms in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer.
Shah MP; Neal JW
Drugs; 2022 Apr; 82(6):649-662. PubMed ID: 35412115
[TBL] [Abstract][Full Text] [Related]
19. Emerging drugs for EGFR-mutated non-small cell lung cancer.
Sukrithan V; Deng L; Barbaro A; Cheng H
Expert Opin Emerg Drugs; 2019 Mar; 24(1):5-16. PubMed ID: 30570396
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors.
Westover D; Zugazagoitia J; Cho BC; Lovly CM; Paz-Ares L
Ann Oncol; 2018 Jan; 29(suppl_1):i10-i19. PubMed ID: 29462254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]